DKN-01 and tislelizumab plus chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

被引：0
|
作者：
Klempner, S. J. [1 ]
Chao, J. [2 ]
Uronis, H. [3 ]
Sirard, C. [4 ]
Kagey, M. [5 ]
Baum, J. [5 ]
Song, J. [6 ]
Wang, J. [7 ]
Sonbol, M. B. [8 ]
Wainberg, Z. A. [9 ]
Ajani, J. A. [10 ]
机构：
[1] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[3] Duke Univ, Med, Duke Canc Ctr, Med Ctr, Durham, NC USA
[4] Leap Therapeut, Clin Dev, Cambridge, MA USA
[5] Leap Therapeut, Translat Med, Cambridge, MA USA
[6] BeiGene Ltd, Biostat, San Mateo, CA USA
[7] BeiGene Ltd, Clin Dev, Beijing, Peoples R China
[8] Mayo Clin, Internal Med Dept, Canc Ctr, Phoenix, AZ USA
[9] UCLA, Med Hematol & Oncol, David Geffen Sch Med, Los Angeles, CA USA
[10] Univ Texas MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1213P
引用
收藏
页码：S1103 / S1104
页数：2
相关论文
共 50 条
  • [21] Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
    Lee, K-W.
    Bai, L-Y.
    Jung, M.
    Ying, J.
    Im, Y-H.
    Oh, D-Y.
    Cho, J. Y.
    Oh, S. C.
    Chao, Y.
    Zhou, P.
    Bao, Y.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S855 - S856
  • [22] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
    Kato, K.
    Xu, R-H.
    Oh, D-Y.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Xu, H.
    Sheng, T.
    Barnes, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [23] Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
    Lang, Wenwang
    Ai, Qi
    Zhang, Wenwen
    Jiang, Qinling
    He, Yulong
    Ouyang, Ming
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).
    Wang, Jie
    Yu, Xinmin
    Lu, Shun
    Hu, Yanping
    Sun, Yuping
    Wang, Zhijie
    Zhao, Jun
    Yu, Yan
    Hu, Chunhong
    Yang, Kunyu
    Feng, Guosheng
    Ying, Kejing
    Zhuang, Wu
    Zhou, Jianying
    Wu, Jingxun
    Wu, Yanjie
    Lin, Xiao
    Liang, Liang
    Yang, Nong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    Moehler, Markus H.
    Oh, Do-Youn
    Kato, Ken
    Spigel, David R.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Zimina, Anastasia V.
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Hirano, Hidekazu
    Wyrwicz, Lucjan S.
    Pazo Cid, Roberto
    Xu, Hui
    Sheng, Tao
    Barnes, Gisoo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
  • [26] Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction
    Peng, Zhi
    Wei, Jia
    Wang, Feng
    Ying, Jieer
    Deng, Yanhong
    Gu, Kangsheng
    Cheng, Ying
    Yuan, Xianglin
    Xiao, Juxiang
    Tai, Yanfei
    Wang, Linna
    Zou, Jianjun
    Zhang, Yanqiao
    Shen, Lin
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3069 - 3078
  • [27] Pelareorep (pela) plus atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
    Arnold, D.
    Goekkurt, E.
    Stein, A.
    Martens, U. M.
    Chater, J.
    Ungerechts, G.
    Loghmani, H.
    Coffey, M.
    Trauger, R.
    Heineman, T. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S899 - S899
  • [28] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [29] Zanidatamab plus chemotherapy for first-line (1L) treatment of HER2+advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
    Elimova, E.
    Ajani, J. A.
    Burris, H. A.
    Denlinger, C. S.
    Iqbal, S.
    Kang, Y-K.
    Kim, J. H.
    Lee, K-W.
    Lin, B.
    Mehta, R.
    Oh, D-Y.
    Rha, S. Y.
    Seol, Y. M.
    Xie, C.
    Garfin, P.
    Ku, G. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S887 - S888
  • [30] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    CANCER RESEARCH, 2022, 82 (12)
12345